Digital health investment rebounded in Q1 2026, reaching $7.4 billion, up from $5.9 billion in the previous quarter, according to CB Insights. The increase was largely driven by a concentration of capital in 19 mega-rounds exceeding $100 million, which collectively accounted for 60% of total funding. Late-stage deals dominated the landscape, with median deal size rising to $108 million—more than double the prior quarter—while eight new unicorns emerged, marking the highest quarterly total in nearly four years.
Healthcare is also capturing a growing share of vertical AI spending, projected to reach $1.5 billion in 2025, more than tripling year-over-year. However, challenges persist in implementation. Less than 20% of enterprise healthcare data is currently usable for AI without significant preparation, reflecting structural limitations in legacy systems originally designed for billing and administrative functions rather than predictive analytics.
Mergers and acquisitions increased by 47% during the quarter, totaling 56 deals, with a clear emphasis on commercial adoption rather than regulatory milestones. Abbott’s $23 billion acquisition of Exact Sciences represented the largest transaction, aimed at scaling its Cologuard screening model globally. Similarly, DeepHealth acquired Gleamer for $269 million, valuing its network of more than 700 hospital contracts. In contrast, companies with limited commercial traction saw reduced valuations despite technical milestones, as illustrated by Oxipit’s minimal revenue performance.
Regulatory developments are also shaping investment flows. The CMS-0057-F mandate requiring electronic prior authorization by January 2027 has accelerated funding into this segment. Companies are pursuing both specialized and platform-based approaches, while partnerships such as Abridge with Availity and Samsung with b.well are embedding capabilities directly into clinical and consumer workflows.
AI-driven drug discovery continues to attract significant capital. Earendil Labs raised $787 million to expand its deep learning platform, which has already generated more than 40 therapeutic programs. Takeda has committed up to $1.7 billion to Iambic Therapeutics, which advanced a drug candidate to investigational new drug status in 24 months, compared to an industry average of six years. Early-stage investments are also targeting emerging therapeutic modalities, including molecular glues and macromolecular treatments.
As deployment accelerates, competition for AI talent is intensifying. Companies such as Tennr and Hippocratic AI are expanding headcount, while major technology firms—including Anthropic—are increasing their presence in healthcare. Nvidia is also strengthening its role as a core infrastructure provider, establishing multiple new digital health partnerships during the quarter.
Click here for the original news story.